Alvogen is rethinking the way generics are brought to market. From your highly selective R&D strategy to our more rigorous manufacturing standards to our consolidated global supply chain, we're creating more meaningful ways to meet the needs of pharmacies and consumers.
Our brand division, Almatica Pharma, Inc. is focused on the acquisition of mature brand Rx products.
Established in 2008, Almatica Pharma has a current portfolio that includes pain, urology, and nonsteroidal anti-inflammatory (NSAIDs).
Almatica’s portfolio includes:
Almatica is led by an experienced brand pharmaceutical management team and our current operations consist of established systems to support all aspects of brand product management including regulatory affairs, sales, marketing, customer service, and pharmacovigilance.
The group’s product portfolio consists of a broad range of leading molecules for the treatment of conditions in the fields of oncology, cardiology, respiratory, neurology and gastroenterology. North America is Alvogen’s largest market with approximately half of the group’s sales. Other key markets include Hungary, Romania, South Korea, Bulgaria, Serbia, Russia, Ukraine, China, Thailand and Taiwan. Contact regional offices for information on product offering in your country. In the U.S., Alvogen focuses on difficult-to-make formulations and high-barrier products.
At our Norwich, New York manufacturing headquarters, Alvogen successfully meets – and often exceeds – quality and compliance requirements.
Would you like to learn more about our portfolio, business development, or do you have an idea for partnership or future collaboration? We would like to hear from you.